Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 7/20 | 0.59 |
| ▸ | MME | P08473 | 5/20 | 0.54 |
| ▸ | ACE | P12821 | 5/20 | 0.54 |
| ▸ | CPA1 | P15085 | 5/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.54 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11059164 | 1.00 | CTSD (0.59) | CTSDMMEACECPA1ACE2 | |
| SCHEMBL30139031 | 0.91 | ACE (0.56) | CTSDMMEACECPA1ACE2 | |
| SCHEMBL30051626 | 0.89 | CTSD (0.57) | CTSDMMEPSMB5 | |
| SCHEMBL3867735 | 0.89 | CTSD (0.53) | CTSDMMEACECPA1ACE2 | |
| SCHEMBL3867739 | 0.89 | CTSD (0.53) | CTSDMMEACECPA1ACE2 | |
| SCHEMBL15692336 | 0.88 | PSMB5 (0.61) | CTSDMMEACECPA1ACE2 | |
| SCHEMBL29658166 | 0.88 | MME (0.60) | CTSDMMEPSMB5 | |
| SCHEMBL29876711 | 0.86 | ACE (0.58) | CTSDMMEACECPA1ACE2 | |
| SCHEMBL15649661 | 0.86 | ACE (0.61) | CTSDMMEACECPA1ACE2 | |
| SCHEMBL15692294 | 0.86 | MME (0.57) | CTSDMMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| US-4465625-A | ANALGESICS | RICHTER GEDEON VEGYESZETI GYAR (HU) | 1984-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | CTSD 503/4885MME 824/4885ACE 1190/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | CTSD 213/4885MME 105/4885ACE 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.